HSD17B6 and neoplasm: Taken together, our outcome demonstrated the influence of GATA1/HSD17B6 regulatory axis in cisplatin resistance in LUAD, adding weight to the importance of therapeutic targets to enhancing tumor chemotherapy sensitivity.